Trial Profile
A Randomized Controlled Study Comparing a DPP4 Inhibitor (Linagliptin) and Basal Insulin (Glargine) in Long-Term Care Residents With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Linagliptin (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 13 Jun 2017 Primary endpoint (Change in A1c at 6 months) has been met, according to the results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 13 Apr 2017 Status changed from recruiting to completed.